Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Grants NorDiag Exclusive European WAVE Rights

NEW YORK, Feb. 9 (GenomeWeb News) - Transgenomic and NorDiag announced today that they have signed an exclusive license and supply agreement to collaborate in colorectal and pancreatic cancer diagnostics.

 

Terms of the deal call for Transgenomic to give NorDiag exclusive European commercial rights to use its Wave system in exchange for an undisclosed licensing fee and commitment to annual purchases by NorDiag.

 

NorDiag uses the Wave system in its Genefec test. The platform is "integral to the automation of the Genefec test," said the companies in a statement.

 

NorDiag has offices in London and Bergen, Norway. The Genefec test is available as a clinical diagnostic in Norway and Sweden.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.